Clinical Trial: Efficacy of YKP3089 in Patients With Photosensitive Epilepsy

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Pharmacodynamic Evaluation of YKP3089 in Epilepsy Patients With a Photo-induced Paroxysmal EEG-Response: Proof of Principle

Brief Summary: The aim of this study is to evaluate the ability of a single oral dose of YKP3089 to abolish or clearly reduce the IPS-induced photo-paroxysmal EEG response in photosensitive epilepsy patients, and to measure the onset and duration of the effect. Several cohorts will be used, to sequentially investigate different doses.

Detailed Summary:
Sponsor: SK Life Science

Current Primary Outcome: Determine if YKP3089 will reduce or abolish the photosensitivity response as compared to placebo. [ Time Frame: At the completion of each cohort ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Assessment of serum concentrations of concomitant AEDs during administration of YKP3089 as compared to the placebo day. Assessment of safety/tolerability at multiple dose levels. [ Time Frame: At the completion of each cohort ]

Original Secondary Outcome: Same as current

Information By: SK Life Science

Dates:
Date Received: February 4, 2008
Date Started: August 2007
Date Completion:
Last Updated: December 26, 2013
Last Verified: December 2013